Undisclosed PD-1 inhibitor
/ BMS, Halozyme
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 08, 2022
SYNC 2021 On-Demand
- "Release date: 11/3/2021; Expiration date: 11/3/2022; Plenary 2: SYNCing to End the Epidemics Through Government."
Online CME
June 08, 2022
Dr Nikhil Bhayani honored member of IAOTP 2022
(YouTube)
- "Dr. Nikhil Bhayani selected as International Healthcare Leader Award in Infectious Disease by the International Association of Top Professionals (IAOTP)"
Video
January 07, 2022
Novel Immunotherapy Combos Target TIM-3 and PD-1/PD-L1 Networks
(OncLive)
- "'The theory here is that you can overcome I/O [immuno-oncology] resistance with a combination of a TIM-3 antibody with a PD-1/PD-L1 antibody,' Fred R. Hirsch, MD, PhD, said during the program....Findings from a meta-analysis published in Frontiers in Oncology in August 2020 illustrate the prognostic impact of TIM-3 expression, according to Hirsch....Paul A. Bunn Jr, MD, who served as moderator for the OncLive program, wondered about the rationale for not testing the combination in upfront settings, where the regimen might be more effective. He also questioned whether a patient who progressed on ICI therapy would respond to repeat administration of an ICI with an added therapy."
Media quote
1 to 3
Of
3
Go to page
1